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Background. The increasing incidence of candidemia and emergence of drug-resistant Candida species are major concerns 
worldwide. Long-term surveillance studies are needed.
Methods. The Fungal Infection Network of Switzerland (FUNGINOS) conducted a 15-year (2004–2018), nationwide, epide-
miological study of candidemia. Hospital-based incidence of candidemia, Candida species distribution, antifungal susceptibility, 
and consumption were stratified in 3 periods (2004–2008, 2009–2013, 2014–2018). Population-based incidence over the period 
2009–2018 derived from the Swiss Antibiotic Resistance Surveillance System (ANRESIS).
Results. A total of 2273 Candida blood isolates were studied. Population and hospital-based annual incidence of candidemia 
increased from 2.96 to 4.20/100 000 inhabitants (P = .022) and 0.86 to 0.99/10 000 patient-days (P = .124), respectively. The pro-
portion of Candida albicans decreased significantly from 60% to 53% (P = .0023), whereas Candida glabrata increased from 18% 
to 27% (P < .0001). Other non-albicans Candida species remained stable. Candida glabrata bloodstream infections occurred pre-
dominantly in the age group 18–40 and above 65 years. A higher proportional increase of C glabrata was recorded in wards (18% 
to 29%, P <  .0001) versus intensive care units (19% to 24%, P =  .22). According to Clinical and Laboratory Standards Institute, 
nonsusceptibility to fluconazole in C albicans was observed in 1% of isolates, and anidulafungin and micafungin nonsusceptibility 
was observed in 2% of C albicans and C glabrata. Fluconazole consumption, the most frequently used antifungal, remained stable, 
whereas use of mold-active triazoles and echinocandins increased significantly in the last decade (P < .0001).
Conclusions. Over the 15-year period, the incidence of candidemia increased. A species shift toward C glabrata was recently 
observed, concurring with increased consumption of mold-active triazoles.
Keywords.  antifungals; candida; candidemia; epidemiology; resistance.
Candida species are the most common cause of nosocomial 
fungal infections [1]. Candidemia is associated with substan-
tial morbidity, mortality, and increased healthcare costs [2, 3]. 
The worldwide incidence of candidemia is difficult to assess, 
and long-term population-based surveillance data are avail-
able from few countries. Reported incidence rates vary sig-
nificantly between 3.2 and 8.4 episodes/100.000 inhabitants 
[4–9].
In a nationwide survey of candidemia performed by the 
Fungal Infection Network of Switzerland (FUNGINOS) be-
tween 1991 and 2000, hospital-based incidence rates remained 
unchanged over the 10-year period [10]. Over the last 2 decades, 
new antifungal agents and new management strategies such as 
antifungal prophylaxis and pre-emptive therapy using triazoles 
or echinocandins have been recommended in high-risk hos-
pital populations, in particular patients with hematological 
malignancies and critically ill patients [1]. Their larger use may 
have influenced the Candida species distribution and antifungal 
susceptibility. Although Candida albicans has been the world-
wide predominant species during decades, a shift to Candida 
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species with reduced fluconazole susceptibility, in particular 
Candida glabrata, has been reported from many countries [11, 
12]. In addition, there are increasing reports of echinocandin-
resistant Candida infections [13–15]. In Switzerland, no shift 
to resistant Candida species was observed in the FUNGINOS 
hospitals over the period 1991–2009 [10, 16]. To evaluate the 
trends in the epidemiology and antifungal drug susceptibility of 
candidemia in Switzerland, FUNGINOS conducted a prospec-
tive study over 15 years from 2004 to 2018.
METHODS
The present prospective survey of candidemia in Switzerland 
was conducted in 5 university and 2 tertiary care university-
affiliated hospitals of the FUNGINOS research network.
Hospital and Population-Based Surveillance Over the Period 2004–2018
For hospital-based surveillance, epidemiological and micro-
biological data of the 7 participating hospitals were included 
over 2004–2018 and stratified in 3 periods (2004–2008, 2009–
2013, 2014–2018). These institutions are distributed across the 
country and play a key role in the national healthcare system. 
All adult hematopoietic stem cell and solid organ transplant-
ations are performed in these 7 hospitals. Five of seven surveyed 
hospitals include affiliated pediatric centers.
For population-based surveillance, microbiological data 
were included from the Swiss Antibiotic Resistance Surveillance 
System (ANRESIS) from 2009 to 2018. The ANRESIS program 
centralizes antibiotic and antifungal resistance data of micro-
organisms from a representative selection of clinical microbi-
ology laboratories [17]. From 2009 to 2018, the annual coverage 
of national laboratories by ANRESIS increased from 60.9% 
to 80.6%. To calculate the incidence rates of candidemia per 
100  000 inhabitants, annual population data were extracted 
from the Federal Statistical Office database and were corrected 
according to the reported coverage by ANRESIS [18]. The study 
has been approved by the Ethical Committee of the Lausanne 
University Hospital as the FUNGINOS national coordinating 
center.
Study Variables
The following variables were recorded by questionnaire survey 
on a yearly basis: hospital activities, number and species of the 
10 most frequent bloodstream pathogens, Candida isolates 
from blood cultures, age and ward distribution of patients with 
candidemia, and consumption of antibiotics and antifungals. 
A Candida isolate from at least 1 blood culture set was defined 
as candidemia. Multiple Candida isolates of the same species 
from the same patient were considered as different episodes of 
candidemia if they occurred more than 4 weeks apart [19]. The 
annual questionnaires were distributed to local investigators 
(infectious diseases specialist(s) and clinical microbiologist(s)) 
at each hospital. The FUNGINOS Data Review Committee 
checked data for completeness and consistency and addressed 
queries to centers. Data on hematopoietic stem cell and solid 
organ transplantations derived from the Federal Office of 
Public Health [20]. 
Consumption of antimicrobial agents was calculated in 
Defined Daily Doses (DDD) according to the 2021 Anatomical 
Therapeutical Chemical/ Defined Daily Dose (ATC/DDD) 
Index of the World Health Organization (WHO), except 
for fluconazole, amphotericin B, and posaconazole. For 
fluconazole, DDDs were calculated on a 0.4 grams basis instead 
of 0.2 grams, reflecting the dose recommended in severe sys-
temic infections. For liposomal amphotericin B, DDDs were 
calculated on a 0.21 grams basis (3  mg/kg for a body weight 
of 70  kg). Posaconazole tablets and intravenous formulations 
were approved in Switzerland since mid-2015. Since the li-
censed maintenance dose of these formulations is 300 mg/day 
compared with 600 mg/day for the oral suspension, DDDs for 
posaconazole were calculated on a 0.6 grams and 0.3 grams 
basis before and after mid-2015, respectively.
Candida Species Identification and Antifungal Susceptibility Testing
The 7 microbiology laboratories affiliated with participating 
hospitals used automated blood culture systems (Bactec 
[Becton Dickinson, Sparks, MD] or BacT/Alert [bioMérieux, 
Marcy l’Etoile, France]).
Over the study period 2004–2013, the Candida bloodstream 
isolates were centralized to the FUNGINOS mycology refer-
ence laboratory, Institute of Microbiology, Lausanne University 
Hospital (Centre hospitalier universitaire vaudois [CHUV]). 
Candida species were identified by standard biochemical assays 
in a test gallery (ATB ID 32 C(R); bioMérieux) and by Matrix-
assisted laser desorption/ionization time-of-flight (MALDI-
TOF) mass spectrometry. In case of discordant identification 
between center and reference laboratory, molecular identifica-
tion was performed by polymerase chain reaction amplification 
and sequencing of the D1/D2 region of the large subunit of the 
28S ribosomal RNA gene (28S rDNA). Antifungal susceptibility 
testing was performed by microtiter broth dilution method using 
the Sensititre YeastOne test panel (TREK Diagnostic System, 
Cleveland, OH). Susceptibility testing included fluconazole, 
voriconazole, caspofungin, and amphotericin B over 2004–2013. 
Posaconazole was tested after 2005 and anidulafungin and 
micafungin were tested after 2010. Over 2014–2018, species iden-
tification was performed at local laboratories and susceptibility 
data were extracted from ANRESIS database. Candida species 
identification and susceptibility testing at local laboratories were 
performed by MALDI-TOF and Sensititre YeastOne or Etest, re-
spectively. One center used VITEK (bioMérieux) for susceptibility 
testing. Only isolates with available minimum inhibitory concen-
tration (MIC) were included. Interpretation (or reinterpretation) 
of antifungal susceptibility was performed according to Clinical 
and Laboratory Standards Institute (CLSI) document M60-Ed2.
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Statistical Analysis
Continuous variables were compared using Student’s t test or 
Mann-Whitney U test, and proportions were compared using 
χ 2 test or Fisher’s exact test, as appropriate. Changes in Candida 
species distribution over time were evaluated with the χ 2 test for 
trend. Linear trends over time were analyzed with the Poisson 
regression model. All P values were based on 2-tailed tests of 
significance (P < .05). Statistical analysis was performed using 
SPSS software, version 22 (IBM SPSS Statistics for Windows, 
Armonk, NY).
RESULTS
Hospital Characteristics and Patient Care Activities Over the Period 
2004–2018
The number of hospital beds, patient-days, admissions, and 
clinical activities at high risk for candidemia from the 7 
participating institutions over the 5-year time periods 2004–
2008, 2009–2013, and 2014–2018 are summarized in Table 1. 
The number of beds, admissions, and patient-days increased 
significantly over the 15-year period, whereas the length of 
hospital stay decreased significantly (P < .0001). Mean annual 
hematopoietic stem cell and solid organ transplantations in-
creased by 75% and 26%, respectively.
Trends of Bloodstream Infections 
Data on the most frequent isolates in bloodstream infections 
(BSIs) were available for 5 hospitals. The top 10 ranking of 
BSIs remained stable over 15  years with the exception of a 
proportional increase of Enterococcus spp and a decrease of 
Streptococcus pneumoniae. Among the 10 most frequently re-
ported bloodstream pathogens, Candida species accounted 
for 2.9% in 2004–2008, 3.6% in 2009–2013, and 2.1% in 2014–
2018. In 2014–2018, Candida BSI ranked 10th (range, 9–11) 
(Supplemental Table 1).
Candida Species Incidence and Distribution
A total of 2273 Candida blood isolates were documented in the 
7 centers over the period 2004–2018. A  trend for increasing 
hospital-based incidence of candidemia was found in the last 
5  years with 0.86 (standard deviation [SD]  =  0.11) and 0.81 
(SD = 0.12) per 10 000 patient-days in 2004–2008 and 2009–
2013 and 0.99 (SD  =  0.09) in 2014–2018 (P  =  .124) (Figure 
1A). Consistently, population-based incidence of candidemia 
from the nation-wide retrospective ANRESIS surveillance in-
creased significantly over the last 5 years from 2.96 (SD = 0.37) 
per 100  000 inhabitants in 2009–2013 to 4.20 (SD  =  0.47) in 
2014–2018 (P = .022).
Hospital-based incidence rates of candidemia per 10  000 
patient-days remained stable for C albicans, Candida tropicalis, 
Candida parapsilosis, Candida krusei, and the other Candida 
species, whereas it increased significantly for C glabrata from 
0.15 per 10 000 patient-days in 2004–2008 and 2009–2013 to 
0.27 in 2013–2018 (P = .008) (Figure 1A).
Over the 15-year study period, C albicans was the most fre-
quent species (58%), followed by C glabrata (21%), C tropicalis, 
and C parapsilosis (each 5%). Candida krusei remained rare 
with 3%. Eight percent of all isolates belonged to other Candida 
spp. No Candida auris was isolated during the study period. The 
proportion of C albicans decreased significantly from 60% in 
2004–2008 to 53% in 2014–2018 (P =  .0023). By contrast, the 
proportion of C glabrata increased from 18% to 27% (P < .0001) 
(Figure 1B). No change was observed in the proportions of 
other Candida species.
Candida Species Distribution According to Patients’ Age and Location in 
the Hospital
Data on Candida species distribution according to patients’ 
age were available from 4 hospitals, representing 52% of all 
candidemias. The highest proportion of C glabrata (23%) was 
found in the age group 18–40 and above 65 years (Figure 2A). 
Candida tropicalis and other Candida spp occurred proportion-
ally more frequently in the age group 18–40  years. Although 
only a limited number of isolates of patients below 18  years 
have been investigated, a tendency to a higher proportion of C 
paraspilosis was observed in this age group.
Data on patients’ hospital location at the time of candidemia 
were available from all 7 hospitals. A  higher proportional 
increase of C glabrata was recorded in wards, from 18% in 
Table 1. Hospital Activities in the Seven Participating Hospitals Over the Period 2004–2018
Years
P Value (r) 2004–2008 2009–2013 2014–2018
Admissions 203 939 (16 456) 233 509 (5529) 271 017 (9136) P < .0001, r = 0.92
Patient-days 1 596 485 (49 017) 1 768 829 (16 784) 1 753 755 (40 072) P = .002, r = 0.74
Length of stay, days 7.9 (0.4) 7.6 (0.2) 6.5 (0.1) P < .0001, r = −0.87
Beds 5067 (192) 5492 (110) 5530 (396) P = .029, r = 0.56
Solid organ transplantations 454 (20.3) 494 (16.6) 571 (39.2) P < .0001, r = 0.86
Hematopoietic stem cell transplantations 409 (26.2) 544 (41.3) 719 (53.8) P < .0001, r = 0.95
 Allogeneic 135 (19.4) 182 (18.3) 247 (12.8)  
 Autologous 275 (15.7) 362 (24.1) 472 (42.7)  
Data are reported as mean annual numbers and standard deviation.
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2004–2008 to 29% in 2014–2018 (P < .0001), than in intensive 
care units, from 19% to 24% (P = .22) (Figure 2B).
Antifungal Susceptibility Testing According to Clinical and Laboratory 
Standards Institute
Availability of susceptibility data varied during the study 
period. Over the whole study period, 88% (n  =  1835) of 
Candida isolates (C albicans, C glabrata, C krusei, C parapsilosis, 
C tropicalis) were tested for fluconazole, 80% (n  =  1681) 
were tested for voriconazole, 63% (n  =  1319) were tested for 
posaconazole, 81% (n  =  1697) were tested for amphotericin 
B, 75% (n = 1564) were tested for caspofungin, 30% (n = 626) 
were tested for anidulafungin, and 32% (n = 662) were tested 
for micafungin. Overall, 33% (n = 207) of all tested Candida 
isolates in 2014–2018 were classified as nonsusceptible (ie, 
susceptible-dose-dependent or resistant) to fluconazole, mainly 
due to the high proportion of C glabrata (Table 2). Fluconazole 
nonsusceptibility among C albicans remained at 1% over the 
15-year period. In C parapsilosis, fluconazole nonsusceptibility 
fluctuated from 6% to 7% to 4% from 2004–2008 to 2009–2013 
and 2014–2018, respectively. Micafungin and anidulafungin 
nonsusceptibility in C albicans and C glabrata remained 
below 2%.
Antibiotic and Antifungal Drugs Consumption
The consumption of broad-spectrum antibiotics with anti-
Pseudomonas aeruginosa activity increased over the 15 years in 
the 7 hospitals (P  <  .0001). The overall antifungal drug con-
sumption increased from 2.12 to 3.65 DDD per 100 patient-
days from 2004 to 2011, and it remained stable afterwards 
(Figure 3A). Fluconazole use remained stable since 2007 (Figure 

















































































Figure 1. (A) Annual incidence of candidemia per 10 000 patient days in the 7 hospitals over the 3 time periods 2004–2008, 2009–2013, and 2014–2018. (B) Species dis-
tribution of Candida bloodstream isolates. Total number of Candida isolates per time period are indicated at the top.
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posaconazole, isavuconazole) increased from 0.37 to 1.21 DDD 
per 100 patient-days during 2004–2018 (P  <  .0001) (Figure 
3C). Voriconazole use increased from 2004 to 2007, remained 
stable until 2015, and decreased thereafter. Posaconazole con-
sumption overtook voriconazole consumption in 2016 (Figure 
3C). Echinocandin use increased from 0.2 to 0.6 DDD per 100 
patient-days from 2004 to 2012 (P < .0001) and remained stable 
thereafter. Liposomal amphotericin B consumption increased 
(P  <  .0001), whereas amphotericin deoxycholate decreased 
(P < .0001) during 2004–2018 (data not shown).
DISCUSSION
This FUNGINOS study provides a longitudinal overview of 
the secular trends of candidemia associated with patient care 
activities. This survey, together with the previous 10-year 
FUNGINOS study, is representative for the entire country 
over a 30-year period and constitutes one of the largest con-
temporary worldwide series of candidemia. Our analysis re-
vealed 3 major findings. The incidence of candidemia showed 
a significant increase. Mold-active triazole and echinocandin 
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Figure 2. (A) Species distribution of Candida bloodstream isolates according to patients’ age over 2004–2018 (4 hospitals). Total number of Candida isolates per age group 
are indicated at the top. (B) Species distribution of Candida bloodstream isolates according to patients’ location in the hospital over 2004–2018 (7 hospitals). Total number of 
Candida isolates per time period and ward are indicated at the top. Other Candida spp included (total numbers): Candida dubliniensis (n = 65), C lusitaniae (n = 20), Candida 
pelliculosa (n = 13), Candida kefyr (n = 11), Candida guilliermondii (n = 8), C norvegensis (n = 8), Candida africana (n = 5), Candida orthopsilosis (n = 4), Candida nivariensis 
(n = 4), Candida fabianii (n = 3), Candida inconspicua (n = 2), Candida palmioleophila (n = 2), Candida rugosa (n = 1), Candida pulcherrima (n = 1).
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was observed after 2013, representing 27% of all candidemias 
in 2014–2018.
The population-based candidemia incidence in our study 
is in line with reports from Sweden (4.7/100 000, 2016)  and 
England (3.2/100 000, 2018), whereas it is higher than that re-
ported in Australia (2.41/100 000, 2014–2015), and lower than 
in Denmark (8.38/100 000, 2013–2015), Spain (8.1/100 000, 
2010–2011), and the United States (8.2/100 000, 2013–2017) 
[4–8, 11]. Multiple reasons may explain large differences 
in population-based candidemia incidences, which may be in-
fluenced by geographical and ecological factors, variability in 
monitoring and reporting systems, studied patient populations, 
infection prevention and control strategies, as well as clinical 
management and antimicrobial use practices [21].
International comparison of hospital-based incidences of 
candidemia is difficult, because they highly depend on the study 
population and time period studied, whereas changes over time 
within a single country, where reporting and monitoring sys-
tems remain stable, may be more accurate. In Switzerland, 
hospital-based incidence rates of candidemia have been studied 
by FUNGINOS using standardized questionnaires since 1991. 
Compared with our previous survey, in which incidence 
rates remained unchanged, we now observed an increase of 
candidemia from 0.49 episodes per 10 000 patient-days to 0.99 
episodes over the last 3 decades [10].
Although the Candida species distribution was stable over 
2 decades, we observed a significant decrease of the propor-
tion of C albicans and an increase of C glabrata since 2014. 
This observation is consistent with data from the United States 
as well as from Australia, Denmark, and Canada from 2004 
to 2015 [5, 11, 12, 14]. The recent emergence of C glabrata 
infections in Switzerland has occurred concomitantly with 
the increased use of mold-active triazoles in the last decade. 
The proportion of other non-albicans Candida species such as 
C parapsilosis and C tropicalis, which increased in southern 
Europe and South America, remained stable in Switzerland, 
ranging 4%–6% [4, 22].
Candida glabrata infections occurred predominantly in pa-
tients hospitalized on wards and in the age group 18–40 years 
and above 65  years. This may reflect the prolonged azole 
exposure for prophylaxis or therapy in patients with malig-
nant hematological diseases or undergoing transplantation 
[23–26].
Overall, acquired antifungal resistance in Candida species 
remains rare in Switzerland. Candida auris BSI has not been 
detected in our country in spite of a look-back analysis to ex-
clude misidentification [27]. Although few cases of acquired 
echinocandin resistance associated with FKS mutations have 
been reported in Switzerland since 2009, we do not have any 
indication of the emergence of FKS mutations based on the low 
echinocandin MICs observed in our survey [28]. Anidulafungin 
and micafungin MICs according to CLSI interpretative criteria 
or commercial Sensititre YeastOne echinocandins epidemio-
logical cutoff values appear sensitive and specific for identifying 
FKS mutations among C albicans and glabrata isolates [29]. 
Although several countries have reported the emergence of 
azole resistance of C parapsilosis, we did not observe such a 
trend in our study [30–32].
Limitations of the present study include differences in clin-
ical practices across the different centers, the lack of indi-
vidual clinical data on comorbidities, the lack of clinical data 























































































































Figure 3. (A) Annual consumption of broad-spectrum antibiotics and antifungals in Defined Daily Doses (DDDs) per 100 patient days over 2004–2018. (B) Annual con-
sumption of antifungals in DDDs per 100 patient days over 2004–2018. (C) Annual consumption of azoles in DDDs per 100 patient days over 2004–2018. Data of 7 hos-
pitals are reported. Broad-spectrum antibiotics include the following: cefepime, piperacillin/tazobactam, imipenem, and meropenem. Antifungals include fluconazole, 
itraconazole, voriconazole, posaconazole, isavuconazole, amphotericin B deoxycholate, liposomal amphotericin B, caspofungin, and anidulafungin. The DDDs were defined 
as follows: cefepime 4 grams, piperacillin/tazobactam 14 grams, imipenem 2 grams, meropenem 3 grams; fluconazole 0.4 grams, itraconazole 0.2 grams, voriconazole 0.4 
grams, posaconazole 0.3–0.6 grams, isavuconazole 0.2 grams, amphotericin B deoxycholate 0.07 grams, liposomal amphotericin B 0.21 grams, caspofungin 0.05 grams, and 
anidulafungin 0.2 grams.
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species, previous antifungal drug exposure, and risk factors for 
candidemia or occurrence of infections due to non-albicans 
Candida species. Despite these limitations, this study, together 
with the previous FUNGINOS survey, provides one of the lar-
gest contemporary longitudinal overviews on candidemia from 
an entire country over a 30-year period. These data may add to 
contemporary initiatives such as ECMM CandiReg, which are 
essential for multinational surveillance of the epidemiology of 
Candida spp [33].
CONCLUSIONS
In conclusion, after 2 decades of stable epidemiology in 
Switzerland, we observed a recent increase of the incidence of 
candidemia with emergence of C glabrata, which now accounts 
for one fourth of bloodstream isolates. The increasing selec-
tion pressure mediated by a larger use of mold-active triazoles 
over the last decade most probably promoted this epidemio-
logical shift. Continued epidemiological surveillance studies 
at the national level are key for monitoring the emergence of 
antifungal resistance and updating guidelines for antifungal 
therapy.
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APPENDIX
Fungal Infection Network of Switzerland (FUNGINOS):
Investigators of the Candidemia Study
Clinical Investigators (Institutions and Persons in alphabetical order):
Thomas  Bregenzer, Anna  Conen, Kantonsspital, Aarau; Kai-
Manuel  Adam, Anna  Conen, Ursula  Flückiger, Nina  Khanna, 
Christina  Orasch, Michael Osthoff, University Hospital, Basel; 
Ulrich  Heininger, Universitätskinderspital, Basel; Mario  Franciolli, 
Ospedale  San  Giovanni, Ente Ospedaliero Cantonale, Bellinzona; 
Lauro  Damonti, Stefan  Zimmerli, University Hospital, Bern; 
Madeleine  Rothen, Claudine  Zellweger, Spitalzentrum, Biel; 
Madeleine Rothen, Philipp Tarr, Kantonsspital, Bruderholz; Felix Fleisch, 
Kantonsspital, Chur; Christian  Chuard, Véronique  Erard, Hôpital 
Cantonal, Fribourg; Stéphane Emonet, Jorge Garbino, Dionysios Neofytos, 
Christian van Delden, University Hospital, Geneva; Daniel Genne, Hôpital 
Communal, La-Chaux-de-Fonds; Pierre-Yves  Bochud, Thierry  Calandra, 
Lauro  Damonti, Véronique  Erard, Frédéric  Lamoth, Oscar  Marchetti, 
Christina  Orasch, University Hospital, Lausanne; Jean-Philippe  Chave, 
Clinique  Bois-Cerf, Clinique  Cécil, and Clinique  La  Source, Lausanne; 
Peter  Graber, Kantonsspital, Liestal; Rita  Monotti, Ospedale  Regionale, 
Ente Ospedaliero Cantonale, Locarno; Enos Bernasconi, Ospedale Civico, 
Ente Ospedaliero Cantonale, Lugano; Marco Rossi, Kantonsspital, Luzern; 
Martin Krause, Kantonsspital, Münsterlingen; Rein-Jan Piso, Kantonsspital, 
Olten; Frank  Bally, Nicolas  Troillet, Institut Central des Hôpitaux 
Valaisans, Sion; Katia Boggian, Kantonsspital, Sankt Gallen; Gerhard Eich, 
Jacques  Gubler, Kantonsspital, Winterthur; Jan  Fehr, Alexander  Imhof, 
Christian  Ruef, Peter  Werner  Schreiber, University Hospital, Zürich; 
Gerhard Eich, Jacques Gubler, Stadtspital Triemli, Zürich; Christoph Berger, 
Universitätskinderspital, Zürich.
Microbiology Laboratory Investigators (Institutions and Persons in 
alphabetical order):
Hans  Fankhauser, Ivo  Heinzer, Kantonsspital, Aarau; 
Daniel Goldenberger, Reno Frei, University Hospital, Basel; Roland Hertel, 
Universitätskinderspital, Basel; Marisa  Dolina, Orlando  Petrini, Istituto 
Cantonale di Microbiologia, Bellinzona; Olivier  Dubuis, Viollier 
Microbiology Laboratories, Bienne; Konrad Mühlethaler, University Hospital, 
Bern; Suzanne  Graf, Kantonsspital, Bruderholz and Kantospital, Liestal; 
Martin  Risch, Eva  Ritzler, Kantonsspital, Chur; Dominique  Fracheboud, 
Hôpital Cantonal, Fribourg; Arnaud Riat, Peter Rohner, Jacques Schrenzel, 
University Hospital, Geneva; Reto  Lienhardt, Hôpital Communal, 
La-Chaux-de-Fonds; Jacques  Bille, Frédéric  Lamoth, University Hospital, 
Lausanne; Corinne  Andreutti-Zaugg, Alberto  Gallusser, Clinique La 
Source, Lausanne; Suzanne  Graf, Kantonsspital, Liestal; Gaby  Pfyffer, 
Kantonsspital, Luzern; Karin  Herzog, Kantonsspital, Münsterlingen; 
Urs  Schibli, Kantonsspital, Olten; Lysiane  Tissière, Institut Central des 
Hôpitaux Valaisans, Sion; Thomas Bruderer, Detlev Schultze, Kantonsspital, 
Sankt Gallen; Reinhard Zbinden, University Hospital, Zürich.
